WESTLAKE VILLAGE, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ((Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the completion of enrollment in DERMIS-1 and DERMIS-2, the Company’s pivotal Phase 3 clinical trials evaluating ARQ-151 (topical roflumilast cream) as a potential topical treatment for plaque psoriasis.
News Ticker
- [ March 31, 2023 ] Product Manager – Cell and Gene Therapy – FUJIFILM – Santa Ana, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] Medical Laboratory Scientist – Clinical Laboratory – Providence – Fullerton, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] Senior Biostatistician – Providence – Irvine, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] Postdoctoral Fellow – Computational Biology and Molecular Dynamics – City of Hope – Duarte, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] QC Microbiology Associate II – B. Braun Medical Inc. – Irvine, CA Los Angeles Biotech Jobs
Copyright © 2021 Biotech Networks, LLC
